Loading...
Market
Which drug will lead the MASH treatment market by end of 2025: Wegovy or Rezdiffra?
2
Resolution / Starting Odds
Wegovy leads market • 25%
Rezdiffra leads market • 25%
Both have equal share • 25%
Other drug leads • 25%
Market analysis reports and pharmaceutical sales data
Story
Novo Nordisk to Seek FDA Approval for Wegovy in Treating MASH After New Data on Liver Fibrosis
Nov 1, 2024, 02:21 PM
Novo Nordisk announced plans to file for FDA approval of Wegovy to treat Metabolic Associated Steatotic Hepatitis (MASH), previously known as fatty liver disease. The decision follows the release of new data indicating the drug's potential benefits beyond weight loss. However, the data does not demonstrate improvement in liver fibrosis, a key metric where Madrigal Pharmaceuticals' Rezdiffra has shown success after its approval earlier this year. Analysts noted that while the Wegovy data is not groundbreaking, it remains significant and could warrant an update to the drug's labeling.
View original story
Similar markets
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Zepbound gains >10% market share over Wegovy • 25%
Zepbound gains 0-10% market share over Wegovy • 25%
Wegovy maintains current market share • 25%
Wegovy gains market share over Zepbound • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Zepbound • 25%
Wegovy • 25%
Saxenda • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%